5440672025-01-012025-03-315440672025-03-315440672024-03-315440672024-04-012025-03-315440672025-01-012025-03-31in-capmkt:OtherExpenses1Member5440672025-01-012025-03-31in-capmkt:OtherExpenses2Member5440672025-01-012025-03-31in-capmkt:OtherExpenses3Member5440672025-01-012025-03-31in-capmkt:OtherExpenses4Member5440672025-01-012025-03-31in-capmkt:OtherExpenses5Member5440672025-01-012025-03-31in-capmkt:OtherExpenses6Member5440672025-01-012025-03-31in-capmkt:OtherExpenses7Member5440672025-01-012025-03-31in-capmkt:OtherExpenses8Member5440672025-01-012025-03-31in-capmkt:OtherExpenses9Member5440672025-01-012025-03-31in-capmkt:OtherExpenses10Member5440672024-04-012025-03-31in-capmkt:OtherExpenses1Member5440672024-04-012025-03-31in-capmkt:OtherExpenses2Member5440672024-04-012025-03-31in-capmkt:OtherExpenses3Member5440672024-04-012025-03-31in-capmkt:OtherExpenses4Member5440672024-04-012025-03-31in-capmkt:OtherExpenses5Member5440672024-04-012025-03-31in-capmkt:OtherExpenses6Member5440672024-04-012025-03-31in-capmkt:OtherExpenses7Member5440672024-04-012025-03-31in-capmkt:OtherExpenses8Member5440672024-04-012025-03-31in-capmkt:OtherExpenses9Member5440672024-04-012025-03-31in-capmkt:OtherExpenses10Member5440672025-01-012025-03-31

ItemsThatWillNotBeReclassifiedToProfitAndLoss1

5440672024-04-012025-03-31

ItemsThatWillNotBeReclassifiedToProfitAndLoss1

5440672025-01-012025-03-31

AuditorDomain1

iso4217:INRiso4217:INRxbrli:shares

544067

INNOVACAP

NOTLISTED

INE0DUT01020

INNOVA CAPTAB LIMITED

Main Board

Equity

2024-04-01

2025-03-31

2025-05-19

2025-05-12

INR

Millions

Quarterly

Fourth quarter

Single segment

Drugs and Pharmaceutical products

2025-05-19

15:38:00

2025-05-19

17:35:00

true

Cash Flow Indirect

Declaration of unmodified opinion

2025-01-01

2025-03-31

Audited

Consolidated

3147410000

33800000

3181210000

2109280000

52950000

-182000000

355160000

19520000

98020000

335170000

2788100000

393110000

39470000

57910000

97380000

295730000

3720000

299450000

572250000

5.17

The above consolidated financial results of Innova Captab Limited (the Company or the Holding Company) and its subsidiaries (Holding and its subsidiaries together referred to as the Group) have been prepared in accordance with and comply in all material aspects with the Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013 (the act) read with relevant rules issued there under and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulation), as amended. The results for the quarter and year ended 31 March 2025 are available on the Company's website i.e. www.innovacaptab.com under investor information section and on the stock exchange website i.e. www.bseindia.com and www.nseindia.com. The Group comprise the following Companies (all of which have been incorporated in India): - Innova Captab Limited (Holding Company) - Univentis Medicare Limited (Wholly-owned subsidiary) - Sharon Bio Medicine Limited (Step-down subsidiary) - Univentis Foundation (Wholly-owned subsidiary) The above consolidated financial results have been reviewed and recommended by Audit Committee at its meeting held on 19 May 2025. The Board of Directors at their meeting held on 19 May 2025 have approved the above results and taken them on record. The statutory auditors of the Company have expressed an unmodified opinion on the audited consolidated financial results for the quarter and year ended 31 March 2025. The Group has only one reportable segment i.e. Drugs and pharmaceutical products as per Ind-AS 108 Operating Segments specified under section 133 of the Companies Act, 2013. Accordingly, the disclosures as per the listing agreement are not applicable to the group. The Group acquired Sharon Bio-Medicine Limited as on 30 June 2023. Accordingly, the statement of audited consolidated financial results includes the financial results of Sharon Bio-Medicine Limited from 01 July 2023. The figures of the last quarter of the year ended 31 March 2025 and the corresponding quarter ended in the previous year, as reported in these annual financial results, are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figures up to the third quarter of the financial year. Also, the figures upto the end of the third quarter had only been reviewed and not subject to audit.

2024-04-01

2025-03-31

Audited

Consolidated

12436760000

120450000

12557210000

7998230000

392180000

-249440000

1167780000

24050000

247790000

1266460000

10847050000

1710160000

267780000

159800000

427580000

1282580000

2650000

1285230000

572250000

22.41

Power and fuel

82750000

Stores and spares consumed

30160000

Commission on sales

24460000

Travelling and conveyance

29080000

Packing charges

28200000

Repairs and maintenance

22730000

Lab consumables

20590000

Sub contracting charges

12740000

Freight charges

10040000

Miscellaneous expenses

74420000

Power and fuel

271430000

Stores and spares consumed

103060000

Commission on sales

100140000

Travelling and conveyance

99500000

Packing charges

94940000

Repairs and maintenance

87190000

Lab consumables

82310000

Sub contracting charges

54030000

Freight charges

48120000

Miscellaneous expenses

325740000

8124290000

225220000

166940000

7440000

6680000

84940000

91620000

122370000

35050000

8772930000

2079950000

3316450000

155190000

526470000

6820000

321050000

4325980000

551000000

6956930000

74210000

15804070000

572250000

9021920000

9594170000

2448940000

99050000

131870000

2679860000

932250000

105590000

1912440000

2018030000

318020000

3268300000

179120000

42320000

40300000

3530040000

6209900000

15804070000

The Companys operations relate to only one reportable segment viz Drugs and Pharmaceuticals. Accordingly, no separate disclosure of segment information is required.

-640420000

-477400000

-31610000

2730000

-293800000

236940000

2880000

247790000

22910000

30280000

4520000

30370000

1750000

630000

64550000

-858620000

851540000

-24050000

237150000

638440000

2540000

1724950000

39080000

167470000

-1515860000

1055050000

114030000

8010000

17680000

915330000

37910000

117280000

155190000

Remeasurement of defined benefit obligation

5720000

Remeasurement of defined benefit obligation

3530000

2000000

880000

3720000

2650000

Audited

true

M/s B S R & Co., LLP

true

2025-07-31